|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0024501,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0144576,
umls-concept:C0205179,
umls-concept:C0205288,
umls-concept:C0205390,
umls-concept:C0332174,
umls-concept:C0337810,
umls-concept:C0442711,
umls-concept:C0543478,
umls-concept:C0949626,
umls-concept:C1140680,
umls-concept:C1274040,
umls-concept:C1511572,
umls-concept:C1514162,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-6-10
|
|
pubmed:abstractText |
The aim of this paper was to assess whether weekly intravenous 60-mg/m2 paclitaxel for 21 weeks is feasible and effective as maintenance treatment in 64 patients with advanced ovarian cancer who had microscopic residual disease after 6 cycles of paclitaxel/platinum-based chemotherapy. Forty-eight patients completed the planned cycles of weekly paclitaxel. The worst toxicities were grade 2 leukopenia in 22.4% of the patients, grade 2 neutropenia in 25.9%, grade 2 sensorial neurotoxicity in 20.7%, and grade 2 motor neurotoxicity in 6.9%. Seventeen patients underwent a third-look surgery that showed a pathological complete response in 6 (35.3%, 95% confidence interval [CI], 17.3%-59.0%) cases. The 3-year progression-free survival rate was 18% (95% CI, 9.6%-33.8%), and the 3-year overall survival rate was 64% (95% CI, 52.0%-78.0%). Weekly low-dose paclitaxel is a feasible and well-tolerated maintenance treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1525-1438
|
|
pubmed:author |
pubmed-author:BallardiniMichelaM,
pubmed-author:ContePier FrancoPF,
pubmed-author:FertonaniCarloC,
pubmed-author:GadducciAngioloA,
pubmed-author:KatsarosDionyssiosD,
pubmed-author:MaggiLorenzoL,
pubmed-author:Members of the After-6 Italian Cooperative Group,
pubmed-author:PasquiniEnzoE,
pubmed-author:PecorelliSergioS,
pubmed-author:ScambiaGiovanniG,
pubmed-author:ZolaPaoloP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
615-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19509559-Adult,
pubmed-meshheading:19509559-Aged,
pubmed-meshheading:19509559-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19509559-Combined Modality Therapy,
pubmed-meshheading:19509559-Dose-Response Relationship, Drug,
pubmed-meshheading:19509559-Drug Administration Schedule,
pubmed-meshheading:19509559-Female,
pubmed-meshheading:19509559-Humans,
pubmed-meshheading:19509559-Middle Aged,
pubmed-meshheading:19509559-Neoplasm, Residual,
pubmed-meshheading:19509559-Neoplasm Staging,
pubmed-meshheading:19509559-Organoplatinum Compounds,
pubmed-meshheading:19509559-Ovarian Neoplasms,
pubmed-meshheading:19509559-Paclitaxel,
pubmed-meshheading:19509559-Second-Look Surgery
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2).
|
|
pubmed:affiliation |
Department of Gynecology and Obstetrics, University of Pisa, Pisa, Italy. a.gadducci@obgyn.med.unipi.it
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
